June THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 295( 83 ) NTT 1. 2. 3. 4. CHOP-R 5. DNA 1
296( 84 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 June 3 1 2003 10 4 1 NTT
June THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 297( 85 ) 1 86 1999 3 Hb 9.7 g/dl, WBC 2200/µl 148.7 cm, 46.8 kg (LevenII/VI) WBC 2,500/µl, Sg 39%, Mo 6%, Eo 3%, Ly 52% RBC 251 10 4 /µl Hb 9.8 g/dl, Ht 28.4%, Plt 8.0 10 4 /µl, Ret 1.1% NCC 48,000/µl, Mgk 32/µl, Reti 2.5%, Erythroid Seri 25.8%, Myeloid Seri 43.1%, BI 2.4%, Siderogram 0: 76%, I: 21%, II: 2%, III:1%, ring: 0% Karyotype 46 XY FAB (International Prognostic Scoring System: IPSS 0.5, Intermediate-1) 2001 12 1 WBC 1,000/µl, Seg 200/µl, CRP G-CSF Panipenem/Betamipron (PAPM/BP) CRP 2002 2 2 (WBC 2,100/µ l, Seg 189/µl) G-CSF PAPM/BP 2002 5 MRSA 3 (WBC 2,400/µl, Seg 456/µl) G-CSF Vancomycin (VCM) 2002 7 4 WBC 1,200/µ l, Seg 240/µ l MRSA Candida albicans G-CSF, VCM AMPH-B 2002 85 5 WBC 600/µ l, My 7%, Me 6%, St 15%, Sg 39%, Mo 5%, Eos 3%, Ba 2%, Ly 21%, Atypical Ly 2% RBC 188 10 4 /µ l Hb 5.6g/dl, Ht 16.7%, Plt 1.6 10 4 /µl, Ret 0.8%, NBT 44% 90% CRP 23 mg/dl β-d- ( 5 pg/ml) G-CSF 100 µ g/ Piperacillin (PIPC) 4 g/ Ceftazidime (CAZ) 2g/ CRP MRSA Gentamicin (GM), Teicoplanin (TEIC), Arbekacin (ABK), VCM, ST (TMP/ SMX) ABK 100 mg/ 4 1,500/µ l
298( 86 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 June Figure 5 9 20 Mirimostim (M-CSF) 800 8 10 8 MRSA Meropenem (MEPM) 1.0 g/ VCM 0.5 g/ 10 14 CRP 20 mg/dl 2002 10 23 (Figure) Pomeroy 64% CD11a, CD11b, CD11c, CD18 (CD35), CD15 NBT NADPH G- CSF 300/µ l
June G-CSF1,500/µ l MRSA THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 299( 87 ) 5 β-d-
300( 88 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 June 2 51 45 2002 10 10 29 38.8 (47,900/µ l) 11 13 37.6 44,900/µ l, 79% 10.2 g/dl, 9.8 /µ l (Cr 1.81 mg/dl, CRP 9.91 mg/dl, UA 11.1 mg/dl) 384 PT 19 APTT 48 35 /µ l, 1.5%, 92.2% (AML) FAB M5b (JALSG) AML201 (Idarubicin Ara-C) 1 Ara-C 2003 4 1 3 4 18 α-streptococcus β -D- 4 18 ( 5 pg/ml) 24 233 pg/ml AMPH-B 0.4 mg/kg/ (Fig. 1) 5 4 Candida tropicalis AMPH-B 1.0 mg/kg/ 26 CT (Fig. 2) AMPH-B 1 mg/kg Micafungin (MCFG) 150 mg/ AMPH-B 30 mg/ MCFG 2 CRP β -D- 6 17 (Fig. 3), Candida tropicalis 10 3 4 /µl 10 /µl 13.17 mg/dl CRP 20 1.88 mg/dl β-d- 1,090 pg/ml 2 583 pg/ml 28 CRP (5.32 mg/dl), β-d- (1,920 pg/ml) MCFG CRP β-d-
June THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 301( 89 ) Fig. 1. Fig. 2. CT Fig. 3. CT 2 3cm AMPH-B 0.5 mg/ Cr 3.1 mg/dl Fluconazole (FLCZ) β-d-cr AMPH-B 1 mg/ Itraconazole 200 mg/ β- D- 200 pg/ml CRP 4 mg/dl
302( 90 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 June AMPH- B AMPH- B Itraconazole CT CT 5mm 2 1 1 AMPH-B AMPH-B 0.4 mg/kg/ AMPH-B MCFG 150mg MCFG 150 300 mg AMPH-B 150 mg Candida tropicalis G-CSF -γ M-CSF
June THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 303( 91 ) 3 66 2002 11 2,500/m l, Hb 8.2 g/dl 81 10 3 /ml 12 26 (Myelodysplastic syndrome: MDS) 2003 2 20 118/70 mmhg, 78/min 1,800/m l, 2.66 10 6 /m l, Hb 9.1 g/dl, HCT 27%, 116 10 3 /m l DIC (ALP 60 IU/l, ChE 2,965 mu/ml) (NCC) 76.5 10 3 /m l Blast 5% MDS-RAEB (refractory anemia with excess of blasts: RARB), IPSS (International Prognostic Scoring System) intermediate-1 VEGA (Table 1) 2003 Table 1. VEGA Cytarabine 80 mg/m 2 civ 1 7 Etoposide 80 mg/m 2 div 1 5 Vindesine 2 mg/body iv 10 12 G-CSF 200 m g/m 2 div 13 Fig. 1. CT
304( 92 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 June 2 26 7 14 17 2022 24 JCS300 29 CT 17 CT (Fig. 1) 23 CT 27 (Fig. 1) (Fig. 2) Absidia Rhizopus Rhizomucor 1.6% 4 60% 5 AMPH-B Fig. 2.
June CT MDS-RAEB neutropenia THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 305( 93 ) 2003 200 1/4 AMPH-B 120 130 20 b-d- AMPH-B1 mg/kg
306( 94 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 June 4 CHOP-R CHOP Rituximab 52 2001 12 2002 8 6 4cm 7,400/m l 16.1% (1,191/m L) IgG 632 mg/dl sil-2r 1,110 U/ml, CD19 74.1% bcl2 ( ) t (14; 18)(q32; q21) CT B cell marker L26 (non-hodgkin s lymphoma: NHL) (duffuse mediumsized cell type, B cell type) stage IIIa, IPI (international prognostic index) low-intermediate risk CHOP Rituximab CHOP-R 7 39 CRP 9.3 mg/dl 2 CT (Fig. 1) 1,400/m l, 6% (84/m l) b-d- 103 pg/ml G-CSF 100 m g/ g - 5g/Sulbactam/Cefoperazone (SBT/CPZ) 5g/ Biapenem (BIPM) 1.2 g/ Clindamycin (CLDM) 1.2 g/ Fluconazole (FLCZ) 200 mg/ Itraconazole (ITCZ) 200 mg/(fig. 2) Itraconazole Micafungin (MCFG)150 mg/ AMPH-B b - D- 5 pg/ml AMPH-B Fig. 1. CT
June THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 307( 95 ) Fig. 2. Fig. 3. AMPH-B CT Itraconazole Itraconazole 200 mg/ (Fig. 2) AMPH-B CT (Fig. 3) Rituximab B Rituximab CHOP Rituximab 7 CHOP-R 1,191/ml 84/m l CD20 15.4% Rituximab CD20 bcl2 t (14; 18)(q32; q21) Rituximab CHOP Rituximab 8 8 CHOP Rituximab 4 2 CHOP Rituximab
308( 96 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 June 5 DNA DNA DNA Febrile neutropenia, real-time PCR in vitro 6 (Human Herpes Virus 6: HHV-6) in vitro HHV-6 DNA DNA (Fig. 1) RNA Cy3 Cy5 DNA GenePix Genomic Profiler Fig. 1. DNA
June Fig. 2. THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 309( 97 ) Fig. 3. (Fig.2) (Fig. 3) real-time PCR U94 chemokine agonist U83 100% U83 U94 (Fig. 4) DNA HHV- 6BHHV-6B U11 U94 U100 (viral ligand for CD46) U83 (chemokine agonist vccl4)
310( 98 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 June Fig. 4. U83 U94 Real-time PCR DNA DNA cross-hybridization in vitro HHV-6B DNA (CMV) (EBV) virushost interaction Celonex Inc (Fariborz Rahbar-Dehghan, Fengchun Ye, Lisa Penny) DNA RNA DNA